% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Nicolay:276211,
      author       = {J. Nicolay$^*$ and S. Melchers$^*$ and J. D. Albrecht$^*$
                      and C. Assaf and E. Dippel and R. Stadler and U. Wehkamp and
                      M. Wobser and J. Zhao and I. Burghaus and S. Schneider and
                      K. Gülow and S. Goerdt and C. M. Schürch and J. Utikal and
                      P. Krammer$^*$},
      title        = {{D}imethyl fumarate treatment in relapsed and refractory
                      cutaneous {T} cell lymphoma - a multicenter phase {II}
                      study.},
      journal      = {Blood},
      volume       = {142},
      number       = {9},
      issn         = {0006-4971},
      address      = {Washington, DC},
      publisher    = {American Society of Hematology},
      reportid     = {DKFZ-2023-01023},
      pages        = {794-805},
      year         = {2023},
      note         = {#EA:A370#LA:D030# / 2023 Aug 31;142(9):794-805},
      abstract     = {Targeted therapies for cutaneous T-cell lymphoma (CTCL) are
                      limited and curative approaches are lacking. Furthermore,
                      relapses and drug induced side effects are major challenges
                      in the therapeutic management of CTCL patients creating an
                      urgent need for new, effective therapies. Pathologic
                      constitutive NF-κB activity leads to apoptosis resistance
                      in CTCL cells and thus represents a promising therapeutic
                      target in CTCL. In a preclinical study we showed the
                      potential of dimethyl fumarate (DMF) to block NF-κB and
                      specifically kill CTCL cells (Nicolay et al.: Blood 2016).
                      To translate these findings into a clinical setting, we
                      performed a multicentric phase II study evaluating oral DMF
                      therapy in 25 patients with CTCL stage Ib-IV over 24 weeks
                      (EudraCT number 2014-000924-11/NCT number NCT02546440).
                      Endpoints were safety and efficacy. We evaluated skin
                      involvement (mSWAT), pruritus, quality of life and blood
                      involvement if applicable as well as translational data. In
                      the skin, 7/23 patients $(30.4\%)$ showed a response with
                      $>50\%$ reduction in mSWAT. Patients with high tumor burden
                      in skin and blood responded best to DMF therapy. Although
                      not generally significant, DMF also improved pruritus in
                      several patients. Response in the blood was mixed, but we
                      confirmed the NF-κB inhibiting mechanism of DMF in the
                      blood. The overall tolerability of the DMF therapy was very
                      favorable with mostly mild side effects. In conclusion, our
                      study presents DMF as an effective and excellently tolerable
                      therapeutic option in CTCL to be further evaluated in a
                      phase III study or real-life patient care as well as in
                      combination therapies.},
      cin          = {A370 / D030},
      ddc          = {610},
      cid          = {I:(DE-He78)A370-20160331 / I:(DE-He78)D030-20160331},
      pnm          = {314 - Immunologie und Krebs (POF4-314)},
      pid          = {G:(DE-HGF)POF4-314},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37217183},
      doi          = {10.1182/blood.2022018669},
      url          = {https://inrepo02.dkfz.de/record/276211},
}